ABSTRACT. MicroRNAs (miRNAs) are key regulators of gene expression in humans. Overexpression or depletion of individual miRNAs is associated with human disease. Current knowledge suggests that the retina is influenced by miRNAs and that dysregulation of miRNAs as well as alterations in components of the miRNA biogenesis machinery are involved in retinal diseases, including agerelated macular degeneration (AMD). Furthermore, recent studies have indicated that the vitreous has a specific panel of circulating miRNAs and that this panel varies according to the specific pathological stress experienced by the retinal cells. MicroRNA (miRNA) profiling indicates subtype-specific miRNA profiles for late-stage AMD highlighting the importance of proper miRNA regulation in AMD. This review will describe the function of important miRNAs involved in inflammation, oxidative stress and pathological neovascularization, the key molecular mechanisms leading to AMD, and focus on dysregulated miRNAs as potential therapeutic targets in AMD.
Introduction
MicroRNAs (miRNAs) are small, single-stranded, endogenous, non-coding RNA molecules with a length of 18-24 nucleotides. They function as epigenetic modifiers by triggering the RNA interference (RNAi) pathway. As RNAi implies, miRNAs interfere with RNA, specifically messenger RNA (mRNA). MicroRNA (miRNA) that binds to mRNA induces either mRNA degradation or translational repression depending on complementary binding strength. Perfectly or near-perfectly complementing pairs will result in mRNA cleavage, resulting in no protein synthesis, while partially complementing pairs will only result in translational repression of the mRNA (Hutvagner & Zamore 2002) . By interfering with mRNA, miRNAs ultimately fine-tune the level of protein synthesis in the cell and are important for normal tissue development and homoeostasis. Several factors can be the cause of abnormal expression or activity of miRNAs such as (i) mutations in the miRNA-encoding genes (Hughes et al. 2011; Iliff et al. 2012; Bykhovskaya et al. 2015; Conte et al. 2015) , (ii) variations in the miRNA target site (Tan et al. 2015; Hauberg et al. 2016) , (iii) changes in genes encoding proteins involved in miRNA biogenesis (Foulkes et al. 2014; Lin & Gregory 2015) , (iv) up/downregulation of proteins that induce expression of miRNAs (Kulshreshtha et al. 2007) and (v) epigenetic modifications of the regions encoding miRNAs (Nomura et al. 2008; Kutty et al. 2010b) , and they may all lead to disease.
More than 2500 miRNAs have been discovered in humans (miRbase.org; Griffiths-Jones 2004; Griffiths-Jones et al. 2006 Kozomara & Griffiths-Jones 2011 , 2014 and they are identified by unique numbers (Ambros et al. 2003) . Analysis of the miRNA repertoire expressed from several distinct human cell types reveals tissuespecific dependencies (Londin et al. 2015) , and numerous miRNAs have been found to be expressed in the retina (Ryan et al. 2006; Arora et al. 2007; Hackler et al. 2010; Karali et al. 2010) . The apparent abundance of miRNAs in this organ is suggested to be responsible for the tight gene regulation required to maintain visual health in a demanding physiological environment. In the mouse eye, 320 miRNAs have been found to be expressed in the retina and 340 in the retinal pigment epithelium (RPE)/choroid (Soundara Pandi et al. 2013) , and until recently, researchers have relied on the assumed evolutionary conservation of miRNA expression profiles in rodents and humans (Arora et al. 2007 ). However, a recent study has analysed the miRNA transcriptome (miRNome) in the human retina by small RNA sequencing (RNA seq) of the neural retina of sixteen healthy individuals and identified 480 miRNAs expressed in this tissue and 416 miRNAs expressed in RPE/choroid (Karali et al. 2016) . Interestingly, analysis of the abundance of the retinal miRNAs revealed that the top five most frequent miRNAs accounted for 70% and the top 20 for almost 90% of the total reads. Almost half of the total reads (44%) were mapped on the three members of the miR-183/96/182 cluster, which reflects their essential role in photoreceptor (PR) function. In the RPE/ choroid, the top 12 most abundantly expressed miRNAs accounted for around 75% of the total reads, where miR-204 contributed almost 35% (Karali et al. 2016) . A comparison of the miRNAs expressed in the human tissue to the corresponding list of miRNAs expressed in the murine counterpart revealed that only one-third of the expressed miRNAs were detected in mouse retina, whereas this number was 40% for the RPE/choroidal miRNAs (Karali et al. 2016 ). However, these particular miRNAs accounted for more than 95% and 90% of the total reads in retina and RPE/choroid, respectively (Karali et al. 2016 ). This finding indicates that the murine miRNA atlas mirrors the human, and findings in mouse models can aid in elucidating the important role of dysregulated miRNAs in human diseases. Finally, it was found that more than half of the miRNAs were expressed in both retina and RPE/choroid, whereas 17% and 29% were retinal and RPE/ choroidal specific, respectively (Karali et al. 2016) . The tissue-specific functional role exerted by these miRNAs is presently being investigated as well as their role in development of neovascular eye disorders.
Research in miRNA profiles associated with cancer has indicated a specific miRNA signature for different types of cancer (Lu et al. 2005; Calin & Croce 2006) . Together with identification of miRNAs circulating in the blood and other biological fluids (e.g. urine, saliva) and the fact that miRNAs are relatively stable due to their inherent resistance to RNase digestion and severe chemicalphysical conditions ), these findings have opened an interesting field of research in the investigation of miRNA fingerprints for various other diseases. Several different methods, including miRNA arrays, reverse transcription (RT)-PCR, RNA seq and bioinformatics, have been utilized to investigate and reveal the type and level of miRNA expression in different retinal diseases, and miRNA dysregulation has already been established in different animal models of retinal diseases including retinitis pigmentosa (Loscher et al. 2007) , retinoblastoma (Mu et al. 2010; Kandalam et al. 2012 ) and diabetic retinopathy (Kovacs et al. 2011) . However, the number of studies comparing differentially expressed miRNAs in patients suffering from AMD compared to healthy control individuals is limited. The limited current knowledge suggests that the vitreous has a specific panel of circulating miRNAs (Ragusa et al. 2013) and that this panel varies according to the specific pathological stress experienced by the retinal cells (Ragusa et al. 2013; Hirota et al. 2015) . Such disease-specific miRNAs are important for our understanding of the complex pathway involved in the retinal diseases but also as potential biomarkers, diagnostic tools or as therapeutic targets. This review will describe the function of some of the most important miRNAs expressed in the retina and focus on miRNAs as potential therapeutic targets in AMD.
MiRNAs in AMD
Age-related macular degeneration (AMD) is an age-related, multifactorial disease, and the primary cause of loss of central vision in elderly in the Western world (Klein et al. 1997; Resnikoff et al. 2004) . Clinically, AMD can be divided into the dry or the neovascular type. The dry type is characterized by atrophy of the PR and RPE cells, probably related to increased diffusion distance from the choroid to the outer retina because of accumulation of debris in Bruch's membrane (BM). This debris may accumulate diffusely or focally to be visible by funduscopy as yellowish deposits in the outer retina, so-called drusen (Klein et al. 2008; Zweifel et al. 2010) . The neovascular type develops because of growth of new vessels from the choriocapillaris through cracks in the pathologically changed BM to invade the retina with a destructive effect on its cellular elements. The new vessels cause subretinal leakage and spontaneous haemorrhage, which may resolve as a fibrous scar or lead to detachment of the RPE from the choroid (Jager et al. 2008) . The exact aetiology of AMD is presently unknown, but a number of molecular mechanisms have been proposed to be involved in the disease pathogenesis such as oxidative stress (Age-Related Eye Disease Study Research 2001; Gu et al. 2003; Zarbin 2004) , inflammation (Mullins et al. 2000; Hageman et al. 2001; Crabb et al. 2002; Fritsche et al. 2013 ) and pathological angiogenesis (Aiello et al. 1994; Kvanta et al. 1996; Lopez et al. 1996; Haines et al. 2006; Fritsche et al. 2013 ; Fig. 1 ). Molecules with a pivotal role in these pathways are therefore attractive targets for the control and treatment of this disease.
MiRNA signatures in patients with AMD
MicroRNAs (miRNAs) are becoming increasingly important in efforts aimed at identifying biomarkers associated with the pathogenesis of a number of diseases. Studies have been undertaken to elucidate specific miRNA profiles in AMD patients. Dry AMD (dAMD) can be difficult to detect in the population due to the absence of clear disease symptoms, and when the condition transforms to the neovascular form, sudden irreversible changes in vision can occur. Therefore, early diagnosis of AMD is important and miRNA profiling might reveal potential diagnostic biomarkers of early stages of the disease.
A clinical study has been conducted to investigate the differential expression of miRNAs in patients with neovascular AMD (nAMD) and healthy controls. In this study, the authors evaluated the plasma miRNAs using high-throughput quantitative real-time PCR, and assessed the diagnostic potential of these miRNAs as biomarkers for AMD (Ertekin et al. 2014) . They examined the expression profiles of 384 miRNAs, and 49 profiles were expressed in both groups. Of these, 11 miRNAs were significantly downregulated in the patient group (miR-21, miR-25-3p, miR-140, miR-146b-5p, miR-192, miR-335, miR-342, miR-374a, miR-410, miR-574-3p and miR-660-5p ) and five were found to be significantly upregulated (miR-17-5p, miR-20a, miR-24, miR-106a and miR-223) compared with the control group (Ertekin et al. 2014) . Moreover, they found 10 miRNAs to be expressed only in the patient group (Ertekin et al. 2014 ). Grassmann et al. (2014) performed next-generation sequencing of circulating miRNAs in plasma from nAMD patients. They identified 203 circulating miRNAs, and of these, three miRNAs (miR-301a-3p, miR-361 and miR-424) were significantly altered in nAMD patients compared to AMD-free controls (Grassmann et al. 2014 ). However, no association was found of these three miRNAs with dAMD. MiR-301a-3p, miR-361 and miR-424 are suggested to regulate pathways involved in angiogenesis and in cellular responses to stress and injury, the transforming growth factor beta and mTOR (Grassmann et al. 2014) . Szemraj et al. (2015) screened serum miRNAs using miRNA arrays and evaluated these by quantitative (q)RT-PCR in a cohort of patients with either dAMD, nAMD or a control group. In this study, they analysed expression levels of 377 miRNAs; 23 miRNAs were found to be upregulated and eight downregulated in AMD patients compared to controls. Of these, five miRNAs differed between the patient groups with the neovascular and dry form (miR-661 and miR-3121 were expressed at significantly higher levels in dAMD patients and miR-889, miR-4258 and Let-7 in nAMD), whereas three did not differ (miR-301-5p, miR-424-5p and miR-438) (Szemraj et al. 2015) . Furthermore, they correlated the miRNA serum levels of these five differentially expressed miRNAs with expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR2, and found a positive correlation on both protein and mRNA levels and the expression of Let-7 in nAMD patients (Szemraj et al. 2015) . The Let-7 miRNA family is known to be pro-angiogenic and highly expressed in retinal tissue, including angiogenic endothelial cells (ECs) .
A recent study profiled miRNAs in the vitreous humour of a small number of patients suffering from nAMD compared to patients with non-vascular pathology (Menard et al. 2016) . The data were obtained by microarrays and validated in a larger cohort by individual TaqMan miRNA assay. An increase in the miR-146a level was found and miR-106b and miR-152 levels were found to be decreased in the vitreous humour of nAMD patients in both assays (Menard et al. 2016) . Interestingly, all three miRNAs have described roles in inflammation and angiogenesis (Lukiw et al. 2012; Haque et al. 2015; Nunes et al. 2015) . Furthermore, they profiled the levels of miR-106b, miR-146a and miR-152 in plasma and these profiles mirror the findings in the vitreous humour. Their findings indicate that certain miRNAs Fig. 1 . Examples of miRNAs dysregulation associated with AMD pathogenesis. Even though the exact aetiology of AMD is presently unknown, the most important molecular mechanisms involved are suggested to be inflammation, oxidative stress and pathological neovascularization. For each of these three mechanisms, prominent miRNAs are indicated. Inflammation: Upregulation of miR-9, miR-125b, miR-146a and miR-155 in retina from AMD patients results in altered regulation of CFH and inflammation. Furthermore, altered macrophage number, localization and phenotype are associated with inflammation and AMD. Manipulation of miR-124 and miR-155 levels seems to be able to modulate inflammation in MCs. Oxidative stress: miR-23a is involved in cytoprotection in response to oxidative stress. Inhibition of miR-184 increases the ezrin protein levels in RPE cells from AMD patients. Furthermore, inhibition of miR-184 in ARPE-19 cells results in downregulation of LAMP-1. Pathological neovascularization: Hypoxia is associated with AMD, and HIF-1 has been found to be significantly upregulated in ischaemic retina. HIF-1 activates VEGF. Members of the miR-17 family are predicted to target the HIF-1 and VEGF genes. Similarly, miR-152 indirectly regulates VEGF and has been found to be downregulated in vitreous humour and plasma from AMD patients. AngiomiRs, such as miR-21, miR-126 and miR-150, regulate angiogenesis. MiR-21 has been found to be downregulated in plasma from patients with AMD. MiR-126 regulates important EC processes and is a requisite for maintenance of the vascular structure. MiR-150 regulates migration, proliferation and tube formation. Development of the AMD phenotype may lead to further perturbation of the miRNA expression pattern resulting in auxiliary progression of the disease. On the left, the normal eye is depicted (purple circle), and with age, the AMD phenotype develops (yellow circle) partly as a consequence of miRNA dysregulation leading to inflammation (red colour), oxidative stress (cayenne colour) and pathological neovascularization (grey colour). Green arrows indicate upregulation whereas blue arrows designate downregulation. In specific, green and blue arrows following miRNA names indicate upregulation or downregulation of the designated miRNAs in AMD patients, respectively. are specific for nAMD, and a less invasive route can obtain this miRNA signature (Menard et al. 2016) .
Unfortunately, the miRNA profiles found in AMD patient serum differed among the different studies described in this section, leaving the question of identification of a specific miRNA signature in serum from AMD patients unanswered or at least inconclusive. The inconsistencies may lie in the size of the patient groups as well as in the patient inclusion criteria. This topic is further discussed in a recent review by Berber et al. (2016) , which also compares miRNA profiling in AMD patients and mouse models of distinct AMD features. However, the identified miRNAs in AMD patients might have a relationship with inflammation, oxidative stress and angiogenesis and therefore not only be potential candidates for novel biomarkers of AMD but could also be important as therapeutic targets or for elucidating the molecular pathogenesis of nAMD.
In the following sections, the current status of the role of miRNAs in inflammation, oxidative stress and pathological neovascularization and how changes in these mechanisms may result in development or protection of AMD will be presented. A comprehensive list of the involved miRNAs and their characteristics is shown in Tables 1, 2 (Majewski et al. 2003; Fisher et al. 2005; Klein et al. 2005; Thakkinstian et al. 2006; Fritsche et al. 2013; Garcia et al. 2015; Bonyadi et al. 2016; Hong et al. 2016; Hughes et al. 2016; Munch et al. 2016) . The CFH protein is a major regulator of the innate immune and inflammatory response, and reductions and/or dysfunction in CFH contributes to excessive complement pathway activation associated with increased complement activity on healthy host cells and a sustained inflammatory response. Several miRNAs have been found to bind to the CFH 3 0 untranslated region (UTR) and appears to be major regulators of CFH expression and thus the inflammatory pathology that characterizes AMD (Lukiw et al. 2012 ; Table 1 and Fig. 1 ). MiR-9, miR-125b, miR-146a and miR-155 have been found to be significantly upregulated in samples of whole retina from AMD patients compared to age-matched healthy controls, and binding sites for all four miRNAs are found in the CFH mRNA 3 0 UTR (Lukiw et al. 2012) . Besides genetic risk factors (like CFH risk alleles) non-genetic risk factors (e.g. smoking history and hypertension) influence response to treatment of AMD (Piermarocchi et al. 2015) .
In the eye, miR-9 plays an important role in maintaining RPE cell function. Depending on cell type and developmental stage, miR-9 has been found to be regulated by retinoic acid, reactive oxygen species (ROS) and pro-inflammatory cytokines, for example tumour necrosis factor alpha-(TNF-a) and interleukin-1 (IL-1) (Bazzoni et al. 2009 ), all of which are found abundantly in the diseased retina (Lukiw & Pogue 2007; Zhao et al. 2008; Bazzoni et al. 2009 ). Furthermore, miR-9 is expressed by ARPE-19 cells and its expression is increased when exposed to a retinoic acid derivative, N-(4-hydroxyphenyl) retinamide (Kutty et al. 2010b) . Epigenetic modifications of the promoter regions of genes encoding miR-9 has been reported to regulate miR-9 expression in ARPE-19 cells, although the role of this epigenetic modification in the RPE pathophysiology are not yet known (Kutty et al. 2010b ). MiR-9 has also been linked to the innate immune response in a report, where they found induction of miR-9 in human monocytes and neutrophils exposed to pro-inflammatory signals (Bazzoni et al. 2009 ) and more recently found to be induced in lipopolysaccharide-activated retinal microglia cells (MC), a widely used model system to simulate infection (Liu et al. 2013 ). In addition, a genetic variant of the IL-8 promoter region was recently found associated with the earlier onset of exudative AMD (Hautamaki et al. 2015) , thereby further implicating miRNAs to play important roles in the retina.
Besides regulating CFH and the innate immune response, numerous studies have also implicated miR-155 in both the adaptive immune response as well as in the development of immune cells (Moffett & Novina 2007; Rodriguez et al. 2007; Thai et al. 2007 ; Table 1 ). Infiltrating lymphocytes and macrophages are often associated with the pathogenesis of AMD, and their release of inflammatory cytokines impairs the critical functions of the RPE cells. MiR-155 is important for maintaining RPE cells and is believed to modulate the response of the cells to inflammatory stimuli (Fig. 1) . As multiple targets are regulated by miR-155 in a cell-type-specific manner, the direct mechanism of action is not clear. Besides CFH, the genes encoding IL-6 and IL-1ß have been shown to be miR-155 targets in a study investigating the role of different miRNAs in uveitis (Zhou et al. 2012) . In this study, expression of miR-155 was decreased in peripheral blood mononuclear cells and dendritic cells of patients with Behcet's disease (a rare inflammatory multiorgan disorder affecting connective tissue) compared to healthy controls. Furthermore, miR-124 and miR-155 have been associated with activation of resting microglia in the brain (Guedes et al. 2013) . MCs are the first responders to inflammation, and in the eye, the resting microglia reside in the layers between the inner and outer nuclear layer of the retina as well as in the choroidal capillaries (EllisBehnke et al. 2013) . Macrophages are the main infiltrating inflammatory cells observed in AMD, and histological specimens demonstrate the presence of these cells in choroidal neovascular membranes (Penfold et al. 1984 (Penfold et al. , 1985 . In AMD patients, macrophage number, localization and phenotype are different from what has been detected in normal eyes. The number of choroidal macrophages is increased and mainly found near breaks in BM. The two activated phenotypes, M1 and M2 macrophages, are associated with cytotoxicity and tissue injury (proinflammatory), and immune suppression, angiogenesis and tissue repair (pro-angiogenic), respectively (Cassetta et al. 2011; Tugal et al. 2013 ). In the normal ageing eye, M2 is the predominant phenotype and plays a protective role. A shift towards the M1 phenotype has been observed in the early stages of AMD, and in the late stages, the M2 phenotype may accelerate angiogenesis (Cao et al. 2011 ). In the resting state, the microglia express high levels of miR-124 and low levels of miR-155, whereas this reverses in the active M1 state. In contrast to the M1 state, the M2 state is observed with upregulated miR-124 and downregulated miR-155 (Guedes et al. 2013 ). This finding indicates that manipulation of the miR-124 and miR-155 levels could modulate the status of the retinal microglia, and in this way limit tissue injury caused by an inflammatory response (Fig. 1) .
Oxidative stress
The retina and particularly the RPE cells reside in a demanding microenvironment with chronic oxidative stress. This tissue, which harbours the lightsensitive PR cells, has the highest oxygen consumption in the human body. The exposure to visible light and numerous photosensitizers and a high-energy demand result in priming for the generation of ROS and subsequent oxidative damage. Fortunately, in the normal eye, oxidative damage is minimized due to the presence of antioxidants (e.g. ß-carotene, vitamins C and E) and efficient repair mechanisms. However, ageing will increase oxidative damage caused by a decrease in antioxidant capacity and impairment of the efficiency of the reparative mechanisms, which may exacerbate the normal age-related changes in the macular area. Several clinical studies have demonstrated a link between oxidative damage and AMD. Thus, drusens related to AMD are composed of biomarkers of oxidative stress (Gu et al. 2003) . Moreover, cigarette smoking, which induces systemic oxidative stress, has been shown to be a major risk factor for AMD and clinical studies have shown that dietary intake of antioxidants slows the progression of the disease (Age-Related Eye Disease Study Research G 2001; Age-Related Eye Disease Study 2 Research 2013). In a recent study, autoantibodies against human macular antigens were screened in sera from elderly with and without AMD (Iannaccone et al. 2015) . Among others, they identified autoantigens against important antioxidant proteins expressed in the retina and the choroid. It was concluded that the identified targets could be mechanistically linked to AMD pathogenesis.
A number of studies have shown that miRNA regulation is involved in cytoprotection in response to oxidative stress (Cheng et al. 2009 ; Tang et al. * miR- (17, 20a, 20b, 106a, 106b, 93) . bFGF = basic fibroblast growth factor, CNV = choroidal neovascularization, CryaB 2009; Table 2 and Fig. 1) . Lin et al. (2011) have investigated the role of miR-23a in modulating RPE cell survival and gene expression in response to oxidative damage. ROS induced RPE cell damage by eliciting changes in multiple genes and subsequently leading to RPE cell death and apoptosis. This apoptotic pathway could be activated by triggering the death receptors by compounds such as the Fas ligand (Ashkenazi & Dixit 1999) . ROSinduced RPE damage plays an important role in the pathogenesis of AMD, and increased expression of Fas has been found in PRs from eyes with the late-stage forms of AMD (Dunaief et al. 2002) . Lin et al. found a significant downregulation of miR-23a in macular RPE cells from donor eyes of AMD patients compared to normal age-matched controls. MiR-23a is believed to be involved in cell growth and apoptosis (Cheng et al. 2005) , oligodendroglia development and myelin formation (Lin & Fu 2009) , and mitochondrial glutamine metabolism and ROS production in human cancer cells (Gao et al. 2009 ). In the study by Lin et al. (2011) , forced overexpression of miR-23a in ARPE-19 cells reduced cell death induced by the oxidant generator, hydrogen peroxide and inhibition of miR-23a abolished the protective effect. They also identified a miR-23a binding site in the 3 0 UTR of the Fas gene and demonstrated the ability of miR-23a to regulate Fas expression in ARPE-19 cells. These results indicate an important antiapoptotic effect of miR-23a against oxidative damage.
MiR-184 is known to be an important modulator of neurological development, apoptosis and cell differentiation Shalom-Feuerstein et al. 2012) . Recently, Murad et al. (2014) elucidated the role of miR-184 in human RPE cells (Fig. 1) . They found an increase in the level of ezrin protein which is important for actin assembly at the phagosome membrane and for regulation of the phagolysosomal fusion (Marion et al. 2011) , in RPE cells from AMD patients when miR-184 was inhibited compared to controls. They were also able to show a reduced uptake of PR outer segments in ARPE-19 cells, when miR-184 was inhibited, indicating a potential role for miR-184 in regulation of phagocytosis in these cells. Murad et al. (2014) investigated the effect of miR-184 on phagocytosis-regulating genes by inhibiting miR-184 in ARPE-19 cells and analysed gene expression by qRT-PCR. Besides showing an increase in EZR mRNA, they found a significant reduction in lysosomal-associated membrane protein 1 (LAMP-1) mRNA. This trend was further emphasized by protein analysis. Co-immunostaining of LAMP-1 and ezrin in ARPE-19 cells revealed partial co-localization, which is in accordance with previous findings of direct molecular interactions between these two proteins in human melanoma cells (Federici et al. 2009 ). Moreover, this interaction is required for the formation of phagocytic vacuoles (Huynh et al. 2007 ) and vesicular sorting (Eskelinen 2006) , and LAMP-1 is believed to be involved in phagocytic digestion of PR outer segments by the RPE, a mechanism comparable to lysosomal digestion in other cell types (Gordiyenko et al. 2010) . Murad et al. (2014) verified their findings in ARPE-19 cells, by showing significant inhibition of miR-184 in RPE from AMD patients together with LAMP-1 downregulation compared with normal RPE (Fig. 1) . Lastly, they demonstrated rescue of the LAMP-1 protein levels in AMD RPE cells transfected with miR-184 plasmid. However, they were not able to show a difference in the protein levels of ezrin between control and AMD primary RPE cultures with low levels of miR-184 and explain this finding by their use of an insensitive analysis method. Nevertheless, they were able to show that inhibition of miR-184, as found in AMD patients, is translated into upregulation of ezrin and downregulation of LAMP-1 protein levels and decreased phagocytosis by the RPE cells. The RPE cells perform a wide variety of functions important for retinal homoeostasis, including disposal of PR outer segments and retaining recyclable material, and therefore is crucial for PR maintenance. Perturbation of this important RPE function, for example by modulation of miR-184, is critical and could lead to the pathophysiology of AMD.
Pathological neovascularization
Choroidal neovascularization (CNV), growth of new blood vessels from the choroid into the retina is one of the hallmarks of nAMD. Sprouting angiogenesis, such as CNV, requires orchestrated organization and activation of several highly specialized endothelial phenotypes: tip, stalk and phalanx cells (Siemerink et al. 2013) . Tip cells are the leading cells of sprouting vessels that migrate into the extracellular matrix in a polarized manner. Together with the stalk cells, the cells that proliferate and generate the lumen of the vessel and thereby bridge the gap between the tip cell and the parent vessel grow towards angiogenic stimuli. The phalanx cells form the innermost layer of the newly formed vasculature (Siemerink et al. 2013) . Such stimuli can be caused by insufficient perfusion of a tissue, which triggers local synthesis of angiogenic factors such as VEGF that stimulates neovascularization in the ischaemic area by binding to membrane-bound receptors on ECs (Fig. 1) . VEGF has been intimately related to this process as the major driving factor, but VEGF alone is not sufficient to cause CNV, which implicates other growth factors, and cytokines such as platelet-derived growth factor (PDGF) (Robbins et al. 1994; Dong et al. 2014) , angiopoietins (Ang) (Otani et al. 1999 ) and TNF-a (Markomichelakis et al. 2005) . Hypoxia has been found to be associated with AMD, but whether this is the cause of the disease or a consequence of the disease still remains to be answered. Nonetheless, the hypoxia-inducible factor 1 (HIF-1) has been found to be significantly upregulated in the ischaemic retina (Ozaki et al. 1999) . HIF-1 is a transcription factor that can activate multiple growth factors and receptors, such as VEGF and PDGF. These growth factors are intimately related to the pathogenesis of nAMD. HIF-1 acts as an oxygen sensor and is the master regulator of the response to hypoxia by binding to hypoxia-responsive elements in the promoter regions of VEGF and PDGF (Fig. 1) .
The hypoxamiRs constitute a specific subgroup of miRNAs differentially expressed as a response to hypoxic stress. The hypoxamiRs expressed in a given cell are believed to be based on both cell type and physiological state, but there appears to be a core group of miRNAs expressed in a variety of cell types as a common response to hypoxia (Kulshreshtha et al. 2007 ). Their general action in hypoxic reprogramming includes strengthening of the HIF adaptive responses by promoting HIF expression and/or activity (Ghosh et al. 2010; Kelly et al. 2011 ) as well as HIFindependent pathways that regulate the protein levels involved in important prosurvival cellular responses under hypoxic stress (Taganov et al. 2006; Zhang et al. 2012) . Expression of hypoxamiRs is regulated on multiple levels including transcription of the primiRNAs (Kulshreshtha et al. 2007; Gorospe et al. 2011 ) and at any level of miRNA biogenesis (Caruso et al. 2010; Wu et al. 2011; Ho et al. 2012 ; Fig. 1 ). Six members of the miR-17 family (miR-17, miR-20a, miR-20b, miR-106a, miR106b and miR-93) share the same seed sequence and are predicted to target the HIF-1a and VEGF-A genes. This has been validated in a mouse model of retinopathy of prematurity, where all members were downregulated during the early steps of neovascularization, in this model reflected in increased levels of HIF-1a and VEGF. Furthermore, the levels of HIF-1a and VEGF-A were found to decrease in human Y79 retinoblastoma cells after transfecting cells with members of the miR-17 family (Nunes et al. 2015) . These members are believed to be important during early angiogenic events and may control the angiogenic switch.
Recently, numerous studies have reported findings from another subgroup of miRNAs: the angiomiRs, miRNAs that are key regulators of angiogenesis (Wang & Olson 2009; Jakob et al. 2012; Mocharla et al. 2013; Kim et al. 2014) , where some are considered to be pro-angiomiRs while others act as anti-angiomiRs (Table 3 ). The significance of miRNA regulation for angiogenesis is further underpinned by the findings of embryonic lethality in a homozygous Dicer knockout mouse (Yang et al. 2005) . Dicer is a multidomain protein involved in the endogenous RNAi pathway where it is responsible for cleavage of pre-miRNAs into the mature miRNA form that activates the RNA-induced silencing complex (RISC). Yang et al. (2005) found that blood vessel formation in the mutant embryos of Dicer knockout mice were severely compromised and expression of VEGF, the VEGFR receptors Flt1 and KDR, and Tie1 was altered. These findings indicate a role of Dicer in embryonic angiogenesis possibly through its role in miRNA processing and the consequent regulation of the expression levels of some key angiogenic factors in the cells. AngiomiRs regulate angiogenesis either cell-autonomously (e.g. miR-126 described below) or non-cellautonomously (e.g. members of the miR-17 family). Perturbation of the level of either kind of angiomiRs can rapidly change the gene expression levels in affected cells and thereby exacerbate the pathogenesis of AMD (Fig. 1) .
MiR-21 has been found to be significantly downregulated in plasma from patients with nAMD compared to controls (Ertekin et al. 2014) . In cell culture studies, this miRNA was found to reduce EC proliferation, migration and their ability to form tubes (Sabatel et al. 2011) . Moreover, overexpression of miR-21 reduces laser-induced CNV in mice, indicating an involvement of miR-21 in inhibition of neovascularization (Sabatel et al. 2011) .
MiR-126 is an EC-specific, cellautonomous miRNA and the first angiomiR to be knocked out in mice. MiR-126 together with miR-146, miR-197 and miR-625 have been identified by miRNA profiling of embryonic stem cell-derived ECs and have also been found to be enriched in ECs of developing mouse embryos (Fish et al. 2008) . Repression of miR-126 levels in vitro shows that this miRNA regulates several important EC processes such as migration, capillary network stability and cell survival, and is a requisite for maintenance of the vascular structure in the zebrafish in vivo (Fish et al. 2008) . Cells with reduced levels of miR-126 were found to be less responsive to growth factors such as VEGF, and noticeably, the expression of the PDGFs was significantly downregulated (Fish et al. 2008 ). In the oxygen-induced retinopathy (OIR) model, the level of miR-126 in the retina was found to be significantly decreased after 5 days in an oxygen chamber (Bai et al. 2011) . Moreover, mice treated with plasmid pCMV-miR-126/liposome mixture via intravitreal injection to restore the miR-126 decrease exhibited reduced retinal neovascularization in the OIR model. By bioinformatic analysis, VEGF and insulin growth factor (IGF)-2 was found to be gene targets of miR-126, binding to the 3 0 UTR of these mRNAs, which is confirmed by Western blotting showing that VEGF and IGF-2 levels were indeed significantly inhibited in the retina of miR-126-injected OIR mice (Bai et al. 2011) . A recent study has conducted a more thorough investigation of miR-126 in angiogenesis, where the retinal vascular phenotype of a miR-126 double-knockout mouse (miR-126 À/À ) was characterized (Zhou et al. 2016) . MiR-126 expression was found to be enriched in ECs in ocular vasculature, and this increase was highest on P28 compared to P1 and P12 as determined by RT-PCR and consistent with the increase in retinal vasculature during these periods of postnatal development of the mouse. Knockout of miR-126 was partially lethal in mice, and surviving mice was used to study the importance of miR-126 in retinal vascular development. Vascular coverage of the retina was greatly decreased in the surviving miR-126 À/À mice indicating a crucial role for this miRNA in developmental angiogenesis (Zhou et al. 2016) . The role of miR-126 in pathological angiogenesis was also elucidated, and 14 days after laser injury of BM, miR-126 was found to be upregulated. Silencing of miR-126 by locked nucleic acid (LNA)-antimiRs repressed the CNV area, and together, these findings suggest an involvement of this miRNA in laser-induced CNV (Zhou et al. 2016) . Surprisingly, overexpression of miR-126 mimics also decreased CNV formation to the same extent as miR-126 antimiRs in the laser-induced CNV model. In vitro studies on ECs suggested that the repressive effect of the miR-126 mimics was via an indirect mechanism and not caused by its effects on ECs. Subretinal delivery of the miR-126 mimics will distribute the miRNAs not only to the choroid but also to the neighbouring RPE cells, where VEGF expression is high and miR-126 levels are lower than in ECs. By ELISA and Western blotting, they confirmed repression of VEGF by miR-126 mimics in ARPE-19 cells in vitro and isolation of RPE cells from miR-126 À/À mice revealed a significantly higher expression of secreted VEGF as compared to cells from WT control mice. They conclude that downregulation of VEGF in the RPE cells partially accounts for the decrease in CNV area by miR-126 mimics in the laser-induced CNV model . Taken together, these findings indicate that modulation of miR-126 expression has a global effect on titrating growth factor signals and consequently disrupts angiogenesis and vascular integrity.
MiR-150 is another EC-specific endogenous inhibitor of pathological angiogenesis and was identified by miRNA array and RT-PCR of retinal RNA isolated from OIR and agematched normoxic mice at P17 to be suppressed in OIR retinas . In normoxic retina, miR-150 is localized in retinal blood vessels, where expression is considerably higher than in neuronal tissue as well as blood vessels from hypoxic retina . MiR-150 regulates migration, proliferation and tube formation in human retinal microvascular endothelial cells (HRMEC) in vitro, most likely through VEGF-independent pathways. CXCR4, DLL4 and FZD4 were identified as potential targets of miR-150, and the gene product of all three was indeed found to be significantly upregulated in blood vessels isolated from OIR mice compared with normoxic control mice. Moreover, expression from CXCR4, DLL4 and FZD4 was significantly inhibited in HRMEC treated with miR-150 mimics, whereas the expression level of various growth factors including VEGF and its receptors was unaffected . This finding was further validated in the OIR model, where miR-150 was found to suppress pathological angiogenesis without altering the expression levels of VEGF, VEGFR-1 and VEGFR-2. Furthermore, miR-150 deficiency increases laser-induced CNV formation in the miR-150 À/À mouse. However, examination of retinal vasculature at P7 of miR-150 À/À and control mice revealed no significant difference, pointing to the fact that miR-150 is important in pathological neovascularization but dispensable during retinal vascular development . Proper modulation of angiomiR levels and thereby angiogenic regulators in the retina can be key to harness excessive pathological neovascularization in this tissue.
MiRNAs as potential targets for treatment of AMD
Current therapies for treatment of AMD include monthly intravitreal injections with anti-VEGF agents for nAMD. However, the response shows individual variation with some patients showing complete remission after only a few injections and others showing a limited response to even a large number of injections. It is believed that most patients experience peaks and troughs of the drug when given as a monthly bolus therapy, which consequently affects vision. Moreover, the need for frequent controls and injections is a burden to both the patient and the healthcare system. This emphasizes the need for a new treatment modality with a more sustained effect which might be achieved by gene therapy (Askou 2014; Corydon 2015) . This treatment modality has been shown to be safe and effective for untreatable rare retinal diseases such as Leber congenital amaurosis which has drawn attention to this therapy as a potential treatment for more common blinding diseases such as AMD (Bainbridge et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008) .
In contrast to the monogenetic diseases, where replacement or knockout of defective genes have proven sufficient, multifactorial diseases such as AMD involving multiple dysregulated pathways are more difficult to treat with one drug target. The first attempts of gene therapy development for AMD have reached clinical trials, and all aim to decrease intraocular levels of anti-angiogenic proteins such as VEGF with gene products delivered by viral vectors (Clinical trial identifier# NCT00109499, NCT01024998, NCT01494805 and NCT01301443). These vectors are effective for local delivery of transgenes, but most vectors have limited cargo space. The exploitation of miRNA regulation of important genes involved in AMD pathogenesis together with the fact that one miRNA can regulate several pathways makes these small molecules interesting targets for gene therapy to treat AMD.
The findings presented in Tables 1, 2 and 3 demonstrate that miRNAs involved in AMD are either upregulated or downregulated in clinical manifestations related to AMD or animal/ cell models of AMD. Downregulation of miRNAs will lead to overexpression of its target gene mRNA and eventually the development of clinical signs similar to those observed in AMD. Examples of downregulated miRNAs in the AMD retina are miR-23a that has been found to protect the RPE cells from oxidative damage when overexpressed in the ARPE-19 cell line (Lin et al. 2011 ) and miR-184 regulating EZR and LAMP1 important for RPE phagocytosis (Murad et al. 2014 ; Fig. 1) .
By delivering specific endogenic miRNA in appropriate amounts, pathological changes in the retina can be reverted. The delivery of a viral vector that incorporates a tissue-specific promoter and a gene encoding the miRNA of choice can do this. Due to the small size of miRNAs, it is possible to harbour multiple miRNAs in the same vector, either targeting the same mRNA for degradation/translational inhibition with an additive effect or target multiple pathways with one vector to obtain a combination effect (Askou et al. 2015) . It has already been shown in a mouse model that CNV can be reduced when mice were treated with a viral vector encoding short hairpin RNAs (shRNAs) targeting VEGF . ShRNAs are artificial small RNA molecules, and when genes encoding shRNAs are delivered to cells, the shRNAs are expressed and the product mimics pri/pre-miRNAs depending on the design. These mimics are processed and loaded into the RISC complex just as the miRNAs. However, concern has been raised whether the high shRNA potency due to high levels of shRNA molecules being expressed in the cell interferes with the endogenous housekeeping miRNA biogenesis (Grimm et al. 2006; Ehlert et al. 2010; Martin et al. 2011) . Moreover, the artificial nature of the shRNAs makes the miRNAs better candidates for gene delivery.
At the opposite extreme, where certain pathological miRNAs are upregulated, important protective proteins are found to be downregulated, leaving the retina vulnerable to pathological events. Examples of miRNAs found to be upregulated in AMD patients are miR-9, miR-125b, miR-146a and miR-155 that are all believed to regulate CFH and the inflammatory response as described (Lukiw et al. 2012 ; Fig. 1 ). Introducing miRNA sponges can regulate overexpressed miRNAs. MiRNA sponges are non-coding RNA molecules carrying miRNA binding sites that competitively sequester the miRNAs from their endogenous target (Bak & Mikkelsen 2014) . Different miRNA inhibitor molecules can be utilized for this purpose such as antagomiRs, tough decoys (TuD) and bulged sponges, where the TuDs and bulged sponges have been found to be superior in miRNA inhibition owing to their stability and number of miRNA binding sites harboured in one RNA transcript compared to, for example, the antagomiRs (Bak et al. 2013b ). Both types of miRNA inhibitors can be delivered by viral vectors and expressed from RNA pol II promoters for targeted gene therapy (Bak et al. 2013a,b) . Moreover, the TuD inhibitors can be clustered and designed as dual-targeting hairpins for simultaneous suppression of two or more miRNAs making them ideal for combination therapy where the goal is to sponge multiple different miRNAs (Hollensen et al. 2013) .
Conclusion
Genomewide association studies have identified links to genes involved in the development of AMD, but there are still missing links in how these genes are modulated and impact disease outcome. MicroRNAs (miRNAs) have been suggested to be modulators of disease genes and retinal homoeostasis, and the identification of important retinal specific miRNAs has been initiated. In healthy tissue, miRNAs are expressed with both spatial and temporal precision emphasizing the importance of obtaining miRNA fingerprints for diseased ocular tissue components, such as RPE, choroid, neuroretina and the vitreous. At present, only a few studies have tried to identify the specific panel of miRNAs that are differentially expressed in AMD patients. Unfortunately, samples from diseased eyes or vitreous humour are difficult to obtain, and only a single study has profiled the miRNA signature found in the vitreous fluid. Minimally invasive screening tools, such as miRNA profiling in serum, has only left preliminary and discrepant results. Additional research in this area might help in identifying the specific circulating miRNA fingerprint for nAMD, and these identified miRNAs should be investigated in animal models mimicking AMD. Unfortunately, most of the miRNAs investigated to date in AMD animal models do not mirror the miRNAs that are differentially regulated in AMD patients, and their role in the disease is still unknown.
Improved knowledge of the miRNA profile in the retina and how molecular mechanisms controlling miRNA biogenesis pathways are distorted in AMD will identify novel therapeutic targets that might be easily manipulated by targeted gene therapy delivering TuDs or miRNAs to allow restoration of miRNA expression profiles in specific diseased tissue. Fortunately, modulation of certain miRNAs in mouse models mimicking AMD ameliorates the phenotype, which indicates that miRNA modulation may become a promising avenue of research. However, the question whether the miRNome found in AMD patients is a cause or a consequence of the disease remains to be answered.
